Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study
Authors:
- Laurie L. BrunetteLBLaurie L. Brunette
- Paulette Y. Mhawech-FaucegliaPMPaulette Y. Mhawech-Fauceglia
- Lingyun JiLJLingyun Ji
- Joseph G. SkeateJSJoseph G. Skeate
- Heike E. BrandHBHeike E. Brand
- Kate LawrensonKate Lawrenson
- Saloni WaliaSWSaloni Walia
- Maurizio Chiriva-InternatiMaurizio Chiriva-Internati
- Susan GroshenSGSusan Groshen
- Lynda D. RomanLRLynda D. Roman
- W. Martin KastW. Martin Kast
- Diane M. Da SilvaDSDiane M. Da Silva
Open Access
- 11 October 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 970
Abstract
Prior small studies have shown increased expression of sperm protein 17 (Sp17) in epithelial ovarian cancer (EOC) tissue and suggest Sp17 as a potential biomarker for EOC. However, how Sp17 expression varies with histology, grade, and stage of EOC and its expression in other ovarian neoplasms has not been defined. It is unknown whether patients with EOC have elevated serum Sp17 levels or if Sp17 expression is associated with survival outcomes. The study included 982 patients with benign, borderline, and malignant ovarian neoplasms and normal ovary. There were 878 patients with tissue only, 39 with serum only, and 65 with matching serum and tissue. Immunohistochemical (IHC) staining with anti-Sp17 antibody was performed on tissue specimens and the intensity scored as weak, moderate, or strong. A sandwich enzyme-linked immunosorbent assay (ELISA) was performed to measure Sp17 sera concentrations. Sp17 expression was most commonly seen in serous cystadenomas (83%) and serous borderline tumors (100%). Of the 773 EOC specimens, 223 (30%) expressed Sp17. Grade and histology were significantly associated with Sp17 expression among EOC specimens (p < 0.001) on both univariate and multivariable analysis, with grade 1 serous adenocarcinomas showing the highest expression (51%). Sp17 expression was limited in other benign and non-epithelial malignant neoplasms. Neither Sp17 tissue expression nor serum concentration correlated with survival outcomes. Serum concentrations were higher in patients with Sp17 tissue expression, and the highest concentrations were noted among patients with serous and clear cell adenocarcinomas. Sp17 is highly expressed in benign, borderline, and low grade malignant serous ovarian neoplasms and can be quantified in serum. Sp17 expression may have diagnostic significance in this subset of patients.Keywords
Funding Information
- Department of Obstetrics and Gynecology, University of Southern California
- Prevent Cancer Foundation
- Clinical and Translational Science Institute, University of Southern California
This publication has 31 references indexed in Scilit:
- Primary Cilium Depletion Typifies Cutaneous Melanoma In Situ and Malignant MelanomaPLOS ONE, 2011
- Primary Cilia Are Decreased in Breast Cancer: Analysis of a Collection of Human Breast Cancer Cell Lines and TissuesJournal of Histochemistry & Cytochemistry, 2010
- Cancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian CancerPLOS ONE, 2010
- Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian CancerJournal of Immunology Research, 2010
- Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cellsBMC Cancer, 2009
- Ovarian Low-grade and High-grade Serous CarcinomaAdvances in Anatomic Pathology, 2009
- Pancreatic Cancer and Precursor Pancreatic Intraepithelial Neoplasia Lesions Are Devoid of Primary CiliaCancer Research, 2009
- Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential TumorsMolecular Cancer Research, 2008
- Characterization of Sp17: a ubiquitous three domain protein that binds heparinBiochemical Journal, 2001
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983